<DOC>
	<DOCNO>NCT00241436</DOCNO>
	<brief_summary>The purpose study evaluate safety , effectiveness , pharmacokinetics pharmacodynamics anastrozole ( ARIMIDEX™ ) treatment boys gynecomastia .</brief_summary>
	<brief_title>Open Label Arimidex Gynecomastia</brief_title>
	<detailed_description />
	<mesh_term>Gynecomastia</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>Signed informed consent/assent ( per local requirement ) , male age 1118 yr . ( 10th prior 19th birthday ) , gynecomastia , one breast measuring ≥ 2 cm diameter ( ultrasound caliper measurement ) decrease prior 3 month period medical history present 12 month less ( date onset base best estimate treat physician discussion patient patient 's parent/guardian ) , normal renal liver thyroid function , evidence hormone produce tumor , evidence hypogonadism androgen resistance . Patients give medication know cause gynecomastia within previous 6 month , involvement planning conduct study ( include AZ staff investigative site staff ) , previous enrollment present study , investigator opinion patient would unable comply study protocol .</criteria>
	<gender>Male</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>